Lumida
/ALEC
⌘K
Alector Inc

Alector Inc

ALEC
$1.50USD↑+2.04%+0.03 today

MARKET CAP

166.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $2

52W RANGE

$1
$3

AI Summary

Stalk
TrimMedium

Despite the mid-June Bearish Exhaustion bounce, ALEC remains in a Stage 4 decline with both long- and medium-term downtrends intact. The exhaustion pattern indicates only a potential counter-trend bounce, not a sustained reversal. Short-term momentum above the 9/21 EMAs improves timing for a sell entry but price remains below key 50- and 200-day DMAs. As a result, medium-term bias stays bearish and sell-side execution should be deferred into resistance zones around the declining 50 DMA and prior support, anticipating rejection.

  • ↑FDA breakthrough therapy for latosinamab underscores regulatory support
  • ↑$503.3M cash runway covers operations until H2 2027
  • ↓GSK ended neuroscience collaboration, eroding partner confidence
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Elector, Inc. (NASDAQ: ECTR) is a biotechnology company specialized in developing breakthrough therapies for neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia (FTD). Leveraging its proprietary Alecto Brain Carrier (ABC) technology, Elector aims to enhance drug delivery across the blood-brain barrier, targeting significant unmet medical needs in the neuroscience field. The company is in an emerging stage as it advances its clinical pipeline, particularly focusing on immunoneurology as a primary theme for future growth.

Bull says

  • ↑FDA breakthrough therapy for latosinamab underscores regulatory support
  • ↑$503.3M cash runway covers operations until H2 2027
  • ↑INVOKE-2 and InFRONT-3 data catalysts due in 2024–25
  • ↑Collaboration revenue projected $60–70M in 2024
  • ↑Proprietary ABC platform enhances blood-brain drug delivery
  • ↑Strong institutional interest; positive momentum and dividend yield

Bear says

  • ↓GSK ended neuroscience collaboration, eroding partner confidence
  • ↓Collaboration revenue down from $133.6M in 2022 to $60–70M
  • ↓ARIA events ~1% incidence could trigger regulatory delays
  • ↓Negative earnings yield and weak profitability strain valuation
  • ↓High volatility and negative growth revisions dampen sentiment
  • ↓Elevated short interest signals prevalent market skepticism

Earnings Call · Q2 2023 · Mgmt. Guidance

Updated 07-10-2026neutral

Transcript signals

Bull points

  • We also have world-class partnerships in which we retain significant rights as well as innovative research and technology portfolios.
  • Regarding our TRUMP2 program, we provide more details about our Invoke2 Phase 2 clinical trial with AL002. The trial is approaching full enrollment, and nearly all eligible participants are rolling over into the long-term extension portion of the study.
  • We will also share with you the outcome of our recent productive agency interactions with the FDA and EMA on our InFRONT3 phase three pivotal trial evaluating latiluzumab in frontotemporal dementia. The enrollment in InFRONT3 is also nearly complete.

Bear points

  • three participants had treatment emergent neurological signs and symptoms, and associated MRI findings consisting of focal vasogenic edema, sulcal effusions, microhemorrhages, and superficial siderosis.
  • the variability of disease progression is considerably less than our initial estimates, which were based on limited data at the start of the trial.
  • A high degree of variability in disease progression rates in both groups rendered the analysis uninformative regarding treatment effects.
Read full transcript analysis ›